Managing Headaches in Systemic Lupus Erythematosus

Initial Risk Stratification

The European League Against Rheumatism emphasizes that headache evaluation in SLE patients must first identify high-risk features that demand immediate comprehensive workup, including fever, altered mental status or confusion, focal neurological signs, immunosuppression, vomiting, and meningeal signs 1, 2
Patients without these high-risk features do not require investigation beyond standard headache evaluation 1

Brain MRI with gadolinium-enhanced T1 sequences and diffusion-weighted imaging (DWI) is mandatory to exclude stroke, hemorrhage, cerebral venous sinus thrombosis, or inflammatory lesions 2
MRI should be performed urgently when high-risk features are present 1, 2
Lumbar puncture with CSF analysis is indicated when meningitis is suspected, particularly in immunosuppressed patients 1, 2
CSF studies should include: cell count, protein, glucose, Gram stain, culture, and viral PCR (HSV, JC virus if clinically indicated) 1, 2

The most dangerous mistake is attributing headache or meningitis to lupus without adequately ruling out infection, particularly in patients receiving immunosuppressants 1
Never assume neurological symptoms are lupus-related without proper imaging and exclusion of infection, stroke, or hemorrhage 2

There is no evidence that headache is more frequent or has unique characteristics in SLE compared to the general population 1

Aseptic meningitis is a rare cause of headache in SLE patients, with a cumulative incidence of less than 1% 1
Infectious meningitis is a higher risk in immunosuppressed patients 1

Combination of glucocorticoids with immunosuppressive agents (usually cyclophosphamide, followed by maintenance with azathioprine) is effective in 60-80% of cases when headache is part of major neuropsychiatric lupus 5, 6
Pulse intravenous methylprednisolone combined with cyclophosphamide is recommended for severe NPSLE, with response rates of 60-75% 2
Clinical improvement should occur within days to 3 weeks with appropriate immunosuppressive therapy 2
Antiplatelet and/or anticoagulation therapy should be administered in antiphospholipid-positive patients, especially when other antiphospholipid syndrome manifestations are present 6
Anticoagulation may be required if thrombotic mechanism is identified 2

Neuropsychiatric manifestations often occur early, with 65% preceding SLE diagnosis, and 50-60% occurring within the first year after diagnosis 1, 7
Previous severe NPSLE manifestations confer at least a fivefold increased risk for subsequent neuropsychiatric events, requiring heightened vigilance 2
Delayed treatment initiation beyond 2 weeks is associated with severe neurological deficits 2